Novo Nordisk cuts full-year sales and profit guidance, stock plunges

Novo Nordisk sharply cut its full-year 2025 sales growth guidance to 8–14% and operating profit growth to 10–16% (at constant exchange rates), down from prior forecasts, causing its shares to plunge 21%. The company attributed the revised outlook to weaker-than-expected performance of Wegovy and Ozempic in the U.S. due to persistent compounding and increased competition, as well as slower international uptake for Wegovy. Concurrently, Maziar Mike Doustdar was appointed CEO effective August 2025. While the news briefly impacted Eli Lilly, analysts largely dismissed a direct read-through, noting Novo's specific challenges with compounding versus Eli Lilly's strong market penetration.

Analysis

Novo Nordisk has announced a significant cut to its full-year 2025 guidance, triggering a 21% decline in its share price. The company now projects sales growth of 8–14% and operating profit growth of 10–16% at constant exchange rates, a sharp reduction from the prior outlook of 13–21% and 16–24%, respectively. Management attributes the revision to several headwinds, primarily the persistent and unlawful mass compounding of its GLP-1 drug in the United States, which has suppressed market penetration for Wegovy. This issue is compounded by increasing competition for Ozempic and a slower-than-expected uptake of Wegovy in certain international markets. The guidance cut also reflects an anticipated slowdown in second-half sales growth and a lower free cash flow projection of DKK 35–45 billion. Concurrently, the company announced a leadership change, with Maziar Mike Doustdar succeeding Lars Fruergaard Jørgensen as CEO in August 2025. While the initial market reaction pulled down competitor Eli Lilly's stock by nearly 5%, analyst commentary from Deutsche Bank suggests this is unwarranted. The rationale is that Novo's challenges are company-specific, particularly its struggle with compounded drugs, a problem Eli Lilly has largely mitigated, suggesting the news could be a positive indicator of market share gains for Lilly's Zepbound and Mounjaro.

Key Decisions for Investors

• Investors in Novo Nordisk should re-evaluate their models based on the significantly lower 2025 growth and cash flow guidance, and closely monitor the full half-year results on August 6 for details on the second-half sales deceleration.
• The appointment of a new CEO from International Operations amidst these challenges introduces both risk and potential for a strategic shift; monitor for the new leader's plan to combat compounding and navigate an increasingly competitive GLP-1 market.
• The sell-off in Eli Lilly may be viewed as a buying opportunity, as analyst commentary suggests Novo's issues are idiosyncratic and could signal competitive strength and market share gains for Lilly's Zepbound and Mounjaro.
• The primary risk factor for Novo Nordisk has shifted to its ability to manage competition and the illicit compounding market, making market share data and regulatory enforcement updates key metrics to watch for the entire GLP-1 sector.